Dallah Healthcare revenue tops SAR 2.1bn in H1 on 11.9% growth

Dallah Healthcare Company announced its financial results for the period ending June 30, 2026, on Monday, posting an 11.9% increase in half-year revenue to SAR 2,121.16 million, up from SAR 1,895.19 million in the same period last year. The growth was supported by improved operations at existing facilities, new acquisitions, and rising demand for specialized healthcare services.

In the second quarter, group revenue rose 4.3% to SAR 1,107.90 million. For the first time, patient visits exceeded one million in a single quarter, growing 8.9% to 1.037 million visits.

Accounting profit down, operating profit up

Net profit attributable to shareholders fell 19.5% in the second quarter to SAR 100.01 million, impacted by non-recurring items totaling SAR 27.8 million. The same quarter in 2025 included a reversal of zakat provisions worth SAR 12.5 million, while the current quarter incurred SAR 15.3 million in operating costs for Mina Emergency Hospital in Makkah during the Hajj season.

Excluding these items, adjusted net profit for the quarter rose 3.2% to SAR 115.34 million, and adjusted earnings per share increased 3.5% to SAR 1.14.

For the first half, net profit declined 34.1% to SAR 184.53 million, affected by non-recurring items totaling SAR 79.2 million—most notably a SAR 51.4 million gain from a real estate fund in 2025. Excluding these, the decrease was 7.4%, with net profit at SAR 199.86 million. Meanwhile, adjusted EBITDA rose 5.02% to SAR 430.7 million.

Eastern Province drives growth; Khobar and Ahsa revenue jumps 112%

Expansion in the Eastern Province led half-year growth, accounting for 73.8% of the group’s total increase in visits, which reached 1.976 million, up 17.2%. Dallah Khobar and Dallah Ahsa hospitals—acquired from March 23, 2025—saw their revenue surge 112.2% in the first half and 22.5% in the second quarter.

The company noted it will use most proceeds from the sale of its stake in Dr. Mohammed Rashid Al-Faqih Company—receiving SAR 466.7 million in July—to reduce existing financing costs, which rose by SAR 24.06 million in the first half. This is expected to positively impact future financial results.

Chairman Tarek Al-Qassabi said, “Sustained growth in patient numbers and revenue is a positive indicator for the future,” expecting continued growth driven by rising patient trust and demand for specialized care, as well as the positive impact of debt reduction from the Al-Faqih deal proceeds.

Dallah Healthcare Group is listed on the Saudi Exchange’s main market under the symbol (4004).